منابع مشابه
Twins in spirit - episode I: comparative preclinical evaluation of [68Ga]DOTATATE and [68Ga]HA-DOTATATE
BACKGROUND Recently, an intra-patient comparison demonstrated that the somatostatin (sst) ligand [(68)Ga]HA-DOTATATE ([(68)Ga]DOTA-3-iodo-Tyr(3)-octreotate) provides PET images comparable to or superior to those obtained with [(68)Ga]DOTATATE. To provide a comprehensive basis for nevertheless observed slight differences in tracer biodistribution and dosimetry, the characteristics of [(68)Ga]HA-...
متن کاملFirst in-human radiation dosimetry of 68Ga-NODAGA-RGDyK
BACKGROUND Integrin-targeting radiopharmaceuticals have potential broad applications, spanning from cancer theranostics to cardiovascular diseases. We have previously reported preclinical dosimetry results of 68Ga-NODAGA-RGDyK in mice. This study presents the first human dosimetry of 68Ga-NODAGA-RGDyK in the five consecutive patients included in a clinical imaging protocol of carotid atheroscle...
متن کاملOptimized production and quality control of 68Ga-DOTATATE
Introduction: Optimized production and quality control of 68Ga-DOTATATE as an efficient and preferable PET radiotracer for somatostatin receptor imaging in neuroendocrine tumors is of great interest. In this study effort has been made to present a fast, efficient, cost-effective and facile protocol for 68Ga-DOTATATE productions for clinical trials. Methods:68Ga...
متن کاملMeningiomas: A Comparative Study of 68Ga-DOTATOC, 68Ga-DOTANOC and 68Ga-DOTATATE for Molecular Imaging in Mice
PURPOSE The goal of this study was to compare the tumor uptake kinetics and diagnostic value of three (68)Ga-DOTA-labeled somatostatin analogues ((68)Ga-DOTATOC, (68)Ga-DOTANOC, and (68)Ga-DOTATATE) using PET/CT in a murine model with subcutaneous meningioma xenografts. METHODS The experiment was performed with 16 male NUDE NU/NU mice bearing xenografts of a human meningioma cell line (CH-157...
متن کاملFDA Approves 18F-Fluciclovine and 68Ga-DOTATATE Products.
T hrough its Priority Review mechanism, the U.S. Food and Drug Administration (FDA) recently approved 2 radiopharmaceutical products for use as diagnostic PET agents. The first, approved on May 27, was Axumin (18F-fluciclovine) injection, indicated for use in PET imaging to identify suspected sites of prostate cancer recurrence in men with elevated levels of prostate-specific antigen (PSA) foll...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Nuclear Medicine
سال: 2013
ISSN: 0161-5505,2159-662X
DOI: 10.2967/jnumed.112.114165